TerrAscend Corp. (TSNDF)
Healthcare · OQX
Fundamentals
Valuation and ratings
TerrAscend Corp. trades at USD0.54, which is 48% above the USD0.28 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 22 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
TSNDF earnings and analyst estimates
Recommendation mix, 3 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About TerrAscend Corp.
TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States. The company manufactures vaporizables, concentrates, topicals, flowers, tinctures, and edibles. It offers its products under the brand name Kind Tree Cannabis, Legend, Valhalla Confections, State Flower Cannabis, Ilera Healthcare, Wana, and Cookies. The company also operates retail dispensaries under the Apothecarium brand name. It serves medical patients and adult-use consumers in North America. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.
TSNDF passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is TerrAscend Corp. (TSNDF) undervalued?
Against our discounted cash flow estimate of USD0.28, TSNDF at USD0.54 is 48% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
When does TSNDF report earnings next?
TerrAscend Corp. is scheduled to report on 6 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for TSNDF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.